S.L.A. Pharma AG - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 25

S.L.A. Pharma AG – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “S.L.A. Pharma AG - Product Pipeline Review - H2 2011” provides data on the S.L.A. Pharma AG’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, S.L.A. Pharma AG’s corporate website, SEC filings, investor presentations and featured press releases, both from S.L.A. Pharma AG and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- S.L.A. Pharma AG - Brief S.L.A. Pharma AG overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of S.L.A. Pharma AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of S.L.A. Pharma AG with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the S.L.A. Pharma AG’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate S.L.A. Pharma AG’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of S.L.A. Pharma AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the S.L.A. Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with S.L.A. Pharma AG.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of S.L.A. Pharma AG and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of S.L.A. Pharma AG; S.L.A. Pharma AG - Key Therapeutics; S.L.A. Pharma AG - Pipeline Overview and Promising Molecules; S.L.A. Pharma AG - News; S.L.A. Pharma AG - Latest Updates; S.L.A. Pharma AG - Pipeline; S.L.A. Pharma AG - Discontinued/Dormant Projects

List of Tables
List of Figures
S.L.A. Pharma AG Snapshot
S.L.A. Pharma AG Overview
Key Information
Key Facts
S.L.A. Pharma AG – Research and Development Overview
Key Therapeutic Areas
S.L.A. Pharma AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
S.L.A. Pharma AG – Pipeline Products Glance
S.L.A. Pharma AG – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
S.L.A. Pharma AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
S.L.A. Pharma AG – Drug Profiles
Diltiazem
Product Description
Mechanism of Action
R&D Progress
Eicosapentaenoic Acid 99%
Product Description
Mechanism of Action
R&D Progress
Metronidazole
Product Description
Mechanism of Action
R&D Progress
Naloxone
Product Description
Mechanism of Action
R&D Progress
Nicotine
Product Description
Mechanism of Action
R&D Progress
S.L.A. Pharma AG – Pipeline Analysis
S.L.A. Pharma AG – Pipeline Products by Therapeutic Class
S.L.A. Pharma AG - Pipeline Products By Target
S.L.A. Pharma AG – Pipeline Products by Route of Administration
S.L.A. Pharma AG – Pipeline Products by Molecule Type
S.L.A. Pharma AG – Recent Pipeline Updates
S.L.A. Pharma AG - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
Phenylephrine Hydrochloride Gel
S.L.A. Pharma AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
S.L.A. Pharma AG – Pipeline by Therapy Area and Indication, H2 2011
S.L.A. Pharma AG – Pipeline by Stage of Development, H2 2011
S.L.A. Pharma AG – Monotherapy Products in Pipeline, H2 2011
S.L.A. Pharma AG – Phase III, H2 2011
S.L.A. Pharma AG - Phase II, H2 2011
S.L.A. Pharma AG - Pipeline By Therapeutic Class, H2 2011
S.L.A. Pharma AG - Pipeline By Target, H2 2011
S.L.A. Pharma AG – Pipeline By Route of Administration, H2 2011
S.L.A. Pharma AG – Pipeline By Molecule Type, H2 2011
S.L.A. Pharma AG – Recent Pipeline Updates, H2 2011
S.L.A. Pharma AG - Discontinued Pipeline Products, 2010
S.L.A. Pharma AG, Other Locations

List of Figures
S.L.A. Pharma AG – Pipeline by Therapy Area and Indication, H2 2011
S.L.A. Pharma AG – Pipeline by Stage of Development, H2 2011
S.L.A. Pharma AG – Monotherapy Products in Pipeline, H2 2011
S.L.A. Pharma AG – Pipeline By Therapeutic Class, H2 2011
S.L.A. Pharma AG - Pipeline By Target, H2 2011
S.L.A. Pharma AG – Pipeline By Route of Administration, H2 2011
S.L.A. Pharma AG – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• eBay - Strong Execution
• SunGard - Profile - US
• SAP AG,(SAP) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Siemens AG,(SI) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• United Internet AG,(UDIRF) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Insight into Samsung Electronics' Notebook PC Business Model